Bli medlem
Bli medlem

Du är här

2016-05-11

Recipharm AB: Bulletin from Extraordinary General Meeting of Recipharm AB (Publ)

At the Extraordinary General Meeting (the "EGM") in Recipharm AB
(publ) on 10 May 2016 the shareholders adopted the resolutions
summarized below:

· On 18 April 2016, Recipharm announced that the Company had signed
two separate agreements to acquire Kemwell's pharmaceutical CDMO
businesses. The EGM resolved pursuant to the proposal by the Board of
Directors to authorize the Board of Directors, during the period
until the next Annual General Meeting (the "AGM"), to issue new
series B shares against payment in kind in the form of all shares in
Kemwell AB.

· The EGM also resolved to authorize the Board of Directors, during
the period until the next AGM, to issue new shares with preferential
rights for existing shareholders. The proceeds in connection with
such share issue shall amount to approximately SEK 850 million before
issue costs. However, if the share issue in kind directed to the
sellers of Kemwell AB is not registered prior to the record date for
the proposed rights issue, the Board of Directors will reduce the
number of shares and then also the proceeds in the rights issue
corresponding to the sellers' prospective share of the rights issue.
The EGM resolved therefore, in case such situation will occur, to
authorize the Board of Directors to carry out a directed share issue
against cash payments to the sellers of Kemwell, where the
subscription price will be the same as in the proposed rights issue
and the number of shares issued will correspond to the number of
shares which the sellers would have subscribed for in the rights
issue if they had received the shares issued in connection with the
share issue in kind prior to the record date for the rights issue.

· Finally, the EGM resolved to authorize the Board of Directors, on
one or several occasions during the period until the next AGM, with
or without deviation from the shareholders' preferential rights, to
resolve on share issues and/or issues of convertible bonds that
involve the issue of or conversion to a maximum number of series B
shares corresponding to ten percent of the total number of shares in
Recipharm with regard to any additional shares in connection with
both the share issue against payment in kind and the rights issue to
be carried out under the authorization above.

For further information please visit www.recipharm.com or contact:
Thomas Eldered, CEO, telephone: +46 8 602 52 10
Björn Westberg, CFO, ir@recipharm.com, telephone: +46 8 602 46 20

This information is published in accordance with the Swedish
Securities Market Act, the Swedish Financial Instruments Trading Act
and/or the regulations of Nasdaq Stockholm. This information was
submitted for publication on 11 May 2016, at 08:30 AM CET.

Recipharm AB (publ)
Corporate identity number 556498-8425
Address Lagervägen 7, SE-136 50 Jordbro, Sweden, Telephone 46 8 602 52
00, Fax 46 8 81 87 03

www.recipharm.com
-----------------------------------------------------------
http://news.cision.com/recipharm-ab/r/bulletin-from-extraordinary-genera...
http://mb.cision.com/Main/9273/2006490/513976.pdf

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.